Armata Pharmaceuticals, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 19.847 million compared to USD 10.315 million a year ago. Basic loss per share from continuing operations was USD 0.55 compared to USD 0.29 a year ago. Diluted loss per share from continuing operations was USD 0.55 compared to USD 0.29 a year ago.

For the full year, the company reported net loss was USD 69.045 million compared to USD 36.917 million a year ago. Basic loss per share from continuing operations was USD 1.91 compared to USD 1.08 a year ago. Diluted loss per share from continuing operations was USD 1.91 compared to USD 1.08 a year ago.